ArticleWorld journal of urology2026
Serenoa Repens-Lycopene-Selenium and Epilobium-Palmitoylethanolamide-Calendula after transperineal prostate biopsy: a tertiary single center experience.
Article in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTransperineal prostate biopsy (TPBx) is the gold standard for the diagnosis of prostate cancer, although it may transiently worsen lower urinary tract symptoms (LUTS). Preventive medical strategies for post-biopsy LUTS are lacking. Phytotherapeutic compounds have demonstrated benefits in LUTS management, but their effectiveness in mitigating urinary and sexual dysfunction following TPBx remains unexplored. MATERIALS AND
methodsThis retrospective analysis included 623 patients who underwent TPBx (November 2023-July 2025) at San Raffaele Hospital, Milan, Italy. Following TPBx, patients either received Serenoa Repens, Lycopene and Selenium (Profluss®) with or without Epilobium-Palmitoylethanolamide-Calendula (Riflog CM®) (i.e. treatment group), or no post-biopsy treatment (control group). LUTS and erectile function (EF) were assessed using the International Prostate Symptom Score (IPSS) and the International Index of Erectile Function (IIEF) at baseline, 1 week, and 1 month after TPBx, respectively. Subgroup analyses were conducted according to baseline IPSS and IIEF severity, and logistic regression models evaluated the association between treatment exposure and LUTS worsening or EF recovery within each IPSS and IIEF category.
resultsMedian PSA and prostate volume were comparable between treatment and control groups. The overall prostate cancer detection was 57%, while clinically significant cancer (ISUP ≥ 2) was detected in 43% of patients. There were 202 (32%) patients with mild IPSS, 341 (55%), with moderate IPSS, and 80 (13%) with severe IPSS at baseline. No differences in baseline IPSS were detected among treatment vs. control groups [12 (IQR: 7-17) vs. 11 (IQR: 7-16), respectively]. Treatment discontinuation at 1 month was higher in patients with moderate/severe LUTS compared to mild LUTS (49-51% vs. 34%, p < 0.001), whereas no significant differences in treatment discontinuation were observed among IIEF categories. Logistic regression analysis showed that the phytotherapeutic combination significantly reduced the risk of IPSS worsening at 1 week in patients with mild LUTS (OR 0.23, 95%CI: 0.10-0.54, p = 0.01), with no effect on IIEF recovery.
conclusionPatients with mild pre-biopsy LUTS treated with post-biopsy phytotherapeutic combination showed reduced odds of short-term IPSS increase at 1-week after biopsy compared to untreated patients. These results are hypothesis-generating and prospective randomized trials are needed to confirm these findings.
Indexed as
Identifiers
42287322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.